Key result
Deviating from recommended cangrelor infusion duration is linked to ~6-point higher 48-hour major cardiovascular events after high-risk PCI.
Why the study?
Premature discontinuation of cangrelor may increase acute thrombosis risk in patients undergoing complex/high-risk PCI, but real-world administration and outcomes data are limited.
Does adherence to the recommended cangrelor infusion duration reduce MACE within 48 hours in patients undergoing complex/high-risk PCI?
Cohort (n=200)
Does adherence to the recommended cangrelor infusion duration reduce MACE within 48 hours in patients undergoing complex/high-risk PCI?
Real-world data suggests frequent deviation from recommended cangrelor infusion durations during complex PCI, which may be associated with increased rates of short-term major adverse cardiovascular events.
Answers are grounded in this paper and cite their sources.
Nonadherent cangrelor infusions were associated with higher early MACE in CHIP; hypothesis-generating and should not yet change practice.
Background Cangrelor reduces thrombotic events in patients undergoing percutaneous coronary intervention (PCI), with the advantage of rapid onset and offset. However, premature discontinuation may increase the risk of acute thrombosis for patients undergoing complex/high‐risk PCI (CHIP). Aims We evaluated the real‐world administration of cangrelor and related health outcomes for CHIP patients. Methods A US retrospective physician panel medical chart review (1/1/2020 to 6/26/2025) included patients 18+ years old who received cangrelor (1st dose = index date) during CHIP. We summarized patients' characteristics in the 6 months pre‐index (baseline), cangrelor dosing and administration (IV bolus and/or infusion), and clinical outcomes within 48 h. We described MACE occurrence by dosing adherence. Results Patients ( n = 200) were mostly male (85.5%), had a mean age of 63 years, and had a BMI of 30.2 kg/m 2 . Most (87.5%) received a cangrelor bolus (30.0 µg/kg) and maintenance infusion (4.0 µg/kg/mins), aligned with intended use recommendations. Of patients analyzed for infusion duration ( n = 134), 64.9% deviated from the recommendation of at least 2 h or PCI length. Forty (29.9%) received cangrelor for less than the recommended duration. Overall, 30 (15%) patients experienced MACE, with a higher proportion of MACE seen in those who deviated from the recommended duration (16.1% [95% CI: 3.5%–23.1%] vs. 10.6% [95% CI: 9.1%–25.5%]). Conclusions Our study provides real‐world insight into cangrelor use and clinical outcomes in CHIP patients, highlighting notable variability in infusion duration and differences in MACE occurrence by dosing adherence. Further comparative effectiveness studies are warranted to examine the potential impact of deviation from intended dose/duration on clinical outcomes in CHIP.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) conducted a cohort in Complex and High-Risk Percutaneous Coronary Interventions (CHIP) (n=200). Deviation from recommended cangrelor infusion duration vs. Adherence to recommended cangrelor infusion duration was evaluated on Major adverse cardiovascular events (MACE) within 48 hours. In patients undergoing complex/high-risk PCI, deviation from the recommended cangrelor infusion duration was associated with higher 48-hour major cardiovascular events compared to adherence.
Synapse has enriched 10 related papers. Consider them for comparative context: